DOES METHYLPHENIDATE DECREASE MUTATION RATES OF CIGARETTE SMOKE IN A MODIFIED AMES ASSAY?**
Cigarette smoke contains a number of cancer-causing compounds, including benzo[a]pyrene (BAP). Metabolic activation of BAP by CYP1A1, which is also upregulated in the presence of BAP, is required to convert the compound into its diol epoxide form, which is then able to cause mutations and DNA damage. Methylphenidate (Ritalin) has been shown to inhibit CYP1A1 activity. In these studies we will use a modified Ames test (supplemented with CYP1A1 enzymes) to examine mutation rates following exposure to cigarette smoke concentrate in the presence and absence of methylphenidate.
Young Harris College Research Initiative
Chisholm, John J. and Schroeder, Jennifer C.
"DOES METHYLPHENIDATE DECREASE MUTATION RATES OF CIGARETTE SMOKE IN A MODIFIED AMES ASSAY?**,"
Georgia Journal of Science, Vol. 77, No. 1, Article 7.
Available at: https://digitalcommons.gaacademy.org/gjs/vol77/iss1/7